Sanara MedTech

SMTI

Market cap $312M

Overview Fund Activity

35.01 USD

+1.05

3.09%

At close Updated Sep 15, 4:00 PM EDT

1 day

3.09%

5 days

-2.34%

1 month

17.96%

3 months

22.11%

6 months

6.41%

Year to date

5.77%

1 year

4.32%

5 years

24.28%

10 years

24.28%

About: Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.

Employees: 141

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

11% more capital invested

Capital invested by funds: $28.3M [Q1] → $31.4M (+$3.13M) [Q2]

4% more funds holding

Funds holding: 49 [Q1] → 51 (+2) [Q2]

2.15% more ownership

Funds ownership: 10.3% [Q1] → 12.45% (+2.15%) [Q2]

16% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 19

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$54

54% upside

Avg. target

$54

54% upside

High target

$54

54% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Yi Chen

$54

Buy

Maintained

18 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about SMTI published over the past 30 days

Sanara MedTech: Growth Remains Strong As Debt Concerns Recede

SMTI's Surgical segment revenue grew 28% year-over-year in Q1 to $25.8 million. Surgical segment adjusted EBITDA was $4.7 million, while THP correspondingly posted a loss of $2.1 million. Management is looking at strategic alternatives for THP while planning to cap further investments at $6 million.

Sanara MedTech: Growth Remains Strong As Debt Concerns Recede

Sanara MedTech Inc. Announces Chief Executive Officer Transition

Seth Yon Appointed President, Chief Executive Officer and Director; Ron Nixon to Remain Executive Chairman FORT WORTH, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced that Seth Yon, Sanara's President and Chief Commercial Officer, has been appointed to the position of President and Chief Executive Officer and will join the Board of Directors, effective September 15, 2025.

Sanara MedTech Inc. Announces Chief Executive Officer Transition

Sanara MedTech Inc. to Present at the Cantor Global Healthcare Conference on September 3, 2025

FORT WORTH, TX, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced that management will present at the Cantor Global Healthcare Conference, which is being held at the New York Marriott Marquis in New York, NY from September 2 – 5, 2025. Management will participate in a fireside chat presentation session on Wednesday, September 3 at approximately 2:45 p.m. Eastern Time.

Sanara MedTech Inc. to Present at the Cantor Global Healthcare Conference on September 3, 2025

Sanara MedTech Inc. (SMTI) Q2 2025 Earnings Call Transcript

Sanara MedTech Inc. (NASDAQ:SMTI ) Q2 2025 Earnings Call August 13, 2025 8:00 AM ET Company Participants Elizabeth B. Taylor - Chief Financial Officer Ronald T.

Sanara MedTech Inc. (SMTI) Q2 2025 Earnings Call Transcript

Zacks Investment Research

Sanara MedTech Inc. (SMTI) Reports Q2 Loss, Tops Revenue Estimates

Sanara MedTech Inc. (SMTI) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.41 per share a year ago.

Sanara MedTech Inc. (SMTI) Reports Q2 Loss, Tops Revenue Estimates

Sanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited)

Net Revenue Increased 28% Year-Over-Year in Q2; Increased 27% Year-Over-Year in First Six Months of 2025 Announces Process to Evaluate Strategic Alternatives for its Tissue Health Plus, LLC Subsidiary FORT WORTH, TX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today reported its financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Summary ● Net revenue increased 28% to $25.8 million, compared to $20.2 million in the second quarter of 2024.

Sanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited)

Sanara MedTech to Report Second Quarter 2025 Financial Results on August 13, 2025

FORT WORTH, TX, July 15, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced it will report its second quarter 2025 financial results on Wednesday, August 13, 2025 before the U.S. financial markets open.

Sanara MedTech to Report Second Quarter 2025 Financial Results on August 13, 2025

Sanara MedTech Inc. Announces Launch of Tissue Health Plus Wound Care Provider Pilot Program

Pilot program designed to provide real-world evidence in the use of Tissue Health Plus' technology platform FORT WORTH, TX, July 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced the recent launch, through its subsidiary, Tissue Health Plus, LLC (“THP”), of its wound care provider pilot program, a first of its kind, value-based wound care offering designed for payers and risk-bearing entities, as well as value-based primary care companies. “We are pleased to announce that, during the second quarter, THP launched a pilot program in partnership with a wound care provider group delivering at-home care for chronic wounds across six states,” said Sam Muppalla, President and CEO of THP.

Sanara MedTech Inc. Announces Launch of Tissue Health Plus Wound Care Provider Pilot Program

Sanara MedTech: Pursuing Rapid Expansion While Debt Levels Climb

Sanara MedTech's surgical revenue grew 26% year-over-year in Q1, with a gross margin of 92%. Surgical adjusted EBITDA was $2.7 million in Q1, while THP correspondingly posted a loss of $2 million. High debt levels and elevated interest expenses are key risks, along with the uncertainty surrounding the commercialization of THP.

Sanara MedTech: Pursuing Rapid Expansion While Debt Levels Climb

Sanara MedTech Inc. (SMTI) Q1 2025 Earnings Call Transcript

Sanara MedTech Inc. (NASDAQ:SMTI ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Ron Nixon - Executive Chairman, Chief Executive Officer Seth Yon - President, Chief Commercial Officer Sam Muppalla - President, Chief Executive Officer of Tissue Health Plus Elizabeth Taylor - Chief Financial Officer Conference Call Participants Matt Park - Cantor Fitzgerald Operator Welcome to the Sanara MedTech First Quarter of 2025 Earnings Conference Call. Please note that this conference call is being recorded and a replay will be available on the Investor Relations page of the company's website shortly.

Sanara MedTech Inc. (SMTI) Q1 2025 Earnings Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™